Sponsored by
This article reports on very impressive results for an experimental vaccine therapy for high grade gliomas with the IDH1 mutation. It is a small phase 1 trial (and we have seen great results in small phase 1 trials not pan out in larger phase 3 trials) but I am optimistic on this one.